Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Mar 2024

Haratake Naoki, Ozawa Hiroki, Morimoto Yoshihiro, Yamashita Nami, Daimon Tatsuaki, Bhattacharya Atrayee, Wang Keyi, Nakashoji Ayako, Isozaki Hideko, Shimokawa Mototsugu, Kikutake Chie, Suyama Mikita, Hashinokuchi Asato, Takada Kazuki, Takenaka Tomoyoshi, Yoshizumi Tomoharu, Mitsudomi Tetsuya, Hata Aaron N, Kufe Donald

Abstract excerpt

INTRODUCTION: Osimertinib is an irreversible EGFR tyrosine kinase inhibitor approved for the first-line treatment of patients with metastatic NSCLC harboring EGFR exon 19 deletions or L858R mutations. Patients treated with osimertinib invariably develop acquired resistance by mechanisms involving additional EGFR mutations, MET amplification, and other pathways. There is no known involvement of the oncogenic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acrylamides
Share to Aniline Compounds

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Indoles

Share to Mucin-1

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-akt

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 37924972
DOI: 10.1016/j.jtho.2023.10.017
PMCID: PMC10939926

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MUC1-C Is a Common Driver of Acquired Osimertinib Resistance in NSCLC.PMID 37924972Read ↗

M1C is a druggable target for NSCLC KRAS G12C mutant tumors resistant to KRAS inhibitorsSemantic proximity Read ↗

Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib.Semantic proximity Read ↗

Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer.Semantic proximity Read ↗

MUC1-C Oncoprotein Integrates a Program of EMT, Epigenetic Reprogramming and Immune Evasion in Human CarcinomasSemantic proximity Read ↗

Characterization of In Vivo Resistance to Osimertinib and JNJ-61186372, an EGFR/Met Bispecific Antibody, Reveals Unique and Consensus Mechanisms of Resistance.Semantic proximity Read ↗

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read ↗

Suppressing c-FOS expression by G-quadruplex ligands inhibits osimertinib-resistant non-small cell lung cancer.Semantic proximity Read ↗

The multifaceted role of MUC1 in tumor therapy resistanceSemantic proximity Read ↗

Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer.Semantic proximity Read ↗

Recurrent Escape from Osimertinib-Induced Senescence Promotes Genomic Instability Associated with Therapeutic ResistanceSemantic proximity Read ↗

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.Semantic proximity Read ↗

Inhibition of MUC1-C Suppresses MYC Expression and Attenuates Malignant Growth in KRAS Mutant Lung Adenocarcinomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.